Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Summary

The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.

Timeline

Start

2018-06-01

Primary completion

2019-12-12

Completion

2020-01-15

Outcome

Outcome not reported

Stopped (Enrollment): “Efficacy did not meet the continuance criteria and DMC recommended to stop enrollment.”

Publications

• Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury S. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC Cancer. 2021 May 24;21(1):593. doi: 10.1186/s12885-021-08085-z.

Drugs

Indications